Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of subcutaneous HS-20117 plus aumolertinib versus intravenous HS-20117 plus aumolertinib in first-line EGFR-mutant non-squamous NSCLC
CTR20263734Phase 3Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2026
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of HS-20117-2, PM1080, almonertinib in non-small cell lung cancer (NSCLC), Non-small cell lung cancer (NS-NSCLC), sponsored by Hansoh Pharmaceutical Group. Started Oct 2026; status: active.
02
Drugs
HS-20117-2PM1080almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20263734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263734.